MedTrace Logo

A Study to Assess the Pharmacokinetics and Food Effect of SR419 in Healthy Subjects

NCT04705077 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-03-25

No results posted yet for this study

Summary

This will be an open-label, single-site, Phase I study to evaluate the PK, safety, and tolerability of SR419 in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

SR419

2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.

Sponsors & Collaborators

  • SIMR (Australia) Biotech Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Thomas Polasek · CMAX Clinical Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2021-03-12
Completion
2021-03-12

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705077 on ClinicalTrials.gov